A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines

Clinical and Vaccine Immunology

Volumn 18, Issue 5, 2011, Pages 736-742

  Koeberling, Oliver ^a   Delany, Isabel ^a   Granoff, Dan M ^b  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BINDING PROTEIN; FACTOR H BINDING PROTEIN; IMMUNOGLOBULIN G; NATIVE OUTER MEMBRANE VESICLE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; FEMALE; GENE EXPRESSION; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; MICE; MICROBIAL VIABILITY; NEISSERIA MENINGITIDIS; SECRETORY VESICLES;

EID: 79955738990     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00542-10     Document Type: Article

References (48)

1. Beernink, P. T., D. A. Caugant, J. A. Welsch, O. Koeberling, and D. M. Granoff. 2009. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J. Infect. Dis. 199:1360-1368.
2. Beernink, P. T., and D. M. Granoff. 2009. The modular architecture of meningococcal factor H-binding protein. Microbiology 155:2873-2883.
3. Beernink, P. T., et al. 2011. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J. Immunol. 186:3806-3814.
4. Beernink, P. T., et al. 2008. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate, factor H-binding protein. Infect. Immun. 76:4232-4240.
5. Bjune, G., J. K. Gronnesby, E. A. Hoiby, O. Closs, and H. Nokleby. 1991. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. 14:125-130. (Discussion, 14:130-132.)
6. Bjune, G., et al. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
7. Bonvehi, P., et al. 2010. Three doses of an experimental detoxified L3- derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults. Clin. Vaccine Immunol. 17:1460-1466.
8. Claassen, I., et al. 1996. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14:1001-1008. (Pubitemid 26271074)
9. Delany, I., R. Grifantini, E. Bartolini, R. Rappuoli, and V. Scarlato. 2006. Effect of Neisseria meningitidis fur mutations on global control of gene transcription. J. Bacteriol. 188:2483-2492.
10. Donnelly, J., et al. 2010. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490-19495.
11. Ferrari, G., et al. 2006. Outer membrane vesicles from group B Neisseria meningitidis Delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6:1856-1866.
12. Finne, J., M. Leinonen, and P. H. Makela. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet ii:355-357.
13. Fisseha, M., et al. 2005. Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination. Infect. Immun. 73:4070-4080.
14. Fredriksen, J. H., et al. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-79. (Discussion, 14: 79-80.)
15. Galloway, Y., P. Stehr-Green, A. McNicholas, and J. O'Hallahan. 2009. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int. J. Epidemiol. 38:413-418.
16. Granoff, D. M. 2010. Review of meningococcal group B vaccines. Clin. Infect. Dis. 50(Suppl. 2):S54-S65.
17. Holst, J. 2007. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum. Vaccin. 3:290-294.
18. Holst, J., et al. 2005. The concept of "tailor-made," protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23:2202-2205.
19. Hou, V. C., O. Koeberling, J. A. Welsch, and D. M. Granoff. 2005. Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J. Infect. Dis. 192:580-590.
20. Jennings, H. J., and C. Lugowski. 1981. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J. Immunol. 127:1011-1018. (Pubitemid 11051148)
21. Keiser, P. B., et al. 2011. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 29:1413-1420.
22. Keiser, P. B., et al. 2010. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA. Vaccine 28:6970-6976.
23. Kelly, C., R. Arnold, Y. Galloway, and J. O'Hallahan. 2007. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am. J. Epidemiol. 166:817-823.
24. Koeberling, O., S. Giuntini, A. Seubert, and D. M. Granoff. 2009. Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin. Vaccine Immunol. 16:156-162.
25. Koeberling, O., A. Seubert, and D. M. Granoff. 2008. Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J. Infect. Dis. 198:262-270.
26. Masignani, V., et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
27. Maslanka, S. E., et al. 1998. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect. Immun. 66:2453-2459.
28. Murphy, E., et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389.
29. Nokleby, H. 2007. Neurological adverse events of immunization: experience with an aluminum adjuvanted meningococcal B outer membrane vesicle vaccine. Expert Rev. Vaccines 6:863-869. (Pubitemid 47607859)
30. Nokleby, H., et al. 2007. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25:3080-3084. (Pubitemid 46505045)
31. O'Hallahan, J., D. Lennon, and P. Oster. 2004. The strategy to control New Zealand's epidemic of group B meningococcal disease. Pediatr. Infect. Dis. J. 23:S293-S298.
32. Oriente, F., V. Scarlato, and I. Delany. 2010. Expression of factor H binding protein of meningococcus responds to oxygen limitation through a dedicated FNR-regulated promoter. J. Bacteriol. 192:691-701.
33. Pajon, R., P. T. Beernink, L. H. Harrison, and D. M. Granoff. 2010. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 28:2122-2129.
34. Sacchi, C. T., et al. 2000. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J. Infect. Dis. 182:1169-1176.
35. Sierra, G. V., et al. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207. (Discussion, 14:208-210.)
36. Steeghs, L., J. Tommassen, J. H. Leusen, J. G. van de Winkel, and P. van der Ley. 2004. Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J. Endotoxin Res. 10:113-119.
37. Sun, Y. H., S. Bakshi, R. Chalmers, and C. M. Tang. 2000. Functional genomics of Neisseria meningitidis pathogenesis. Nat. Med. 6:1269-1273.
38. Tappero, J. W., et al. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 281:1520-1527. (Pubitemid 29200936)
39. Thornton, V., et al. 2006. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24:1395-1400. (Pubitemid 43222049)
40. Trotter, C. L., N. J. Gay, and W. J. Edmunds. 2006. The natural history of meningococcal carriage and disease. Epidemiol. Infect. 134:556-566.
41. van der Ley, P., et al. 2001. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect. Immun. 69:5981-5990.
42. van de Waterbeemd, B., et al. 2010. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28:4810-4816.
43. Vu, D. M., T. T. Wong, and D. M. Granoff. 2011. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine 29:1968-1973.
44. Welsch, J. A., R. Rossi, M. Comanducci, and D. M. Granoff. 2004. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J. Immunol. 172:5606-5615.
45. Westphal, O., K. Jann, and K. Himmelspach. 1983. Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Prog. Allergy 33:9-39.
46. Weynants, V., et al. 2009. Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect. Immun. 77:2084-2093.
47. Weynants, V. E., et al. 2007. Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis. Infect. Immun. 75:5434-5442.
48. Zollinger, W. D., et al. 2010. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine 28:5057-5067.